{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T22:37:21Z","timestamp":1790289441266,"version":"4.1.0"},"reference-count":37,"publisher":"Association for Research in Vision and Ophthalmology (ARVO)","issue":"8","license":[{"start":{"date-parts":[[2020,7,29]],"date-time":"2020-07-29T00:00:00Z","timestamp":1595980800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Trans. Vis. Sci. Tech."],"published-print":{"date-parts":[[2020,7,29]]},"DOI":"10.1167\/tvst.9.8.43","type":"journal-article","created":{"date-parts":[[2020,7,29]],"date-time":"2020-07-29T15:31:28Z","timestamp":1596036688000},"page":"43","source":"Crossref","is-referenced-by-count":45,"title":["Ranibizumab Population Pharmacokinetics and Free VEGF Pharmacodynamics in Preterm Infants With Retinopathy of Prematurity in the RAINBOW Trial"],"prefix":"10.1167","volume":"9","author":[{"given":"Matthew","family":"Fidler","sequence":"first","affiliation":[{"name":"Pharmacometrics Ophthalmology, Novartis Pharmaceuticals Corporation, Fort Worth, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian W.","family":"Fleck","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Princess Alexandra Eye Pavilion, Edinburgh, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Stahl","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University Medical Center, Greifswald, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Marlow","sequence":"additional","affiliation":[{"name":"Academic Neonatology, UCL Elizabeth Garrett Anderson Institute for Women's Health, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James E.","family":"Chastain","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research, Inc., Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Li","sequence":"additional","affiliation":[{"name":"Novartis Pharma, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Lepore","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Gemelli Foundation IRCSS, Catholic University of the Sacred Heart, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James D.","family":"Reynolds","sequence":"additional","affiliation":[{"name":"Ross Eye Institute, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael F.","family":"Chiang","sequence":"additional","affiliation":[{"name":"Casey Eye Institute, Oregon Health & Science University, Portland, OR, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alistair R.","family":"Fielder","sequence":"additional","affiliation":[{"name":"Department of Optometry and Visual Science, City, University of London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the RAINBOW study group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"27","reference":[{"key":"bib1","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1016\/S0140-6736(13)60178-6","article-title":"Retinopathy of prematurity","volume":"382","author":"Hellstrom","year":"2013","journal-title":"Lancet"},{"key":"bib2","doi-asserted-by":"publisher","first-page":"1065\u20131070 e1061","DOI":"10.1016\/j.ophtha.2007.08.050","article-title":"Vitreous levels of stromal cell-derived factor 1 and vascular endothelial growth factor in patients with retinopathy of prematurity","volume":"115","author":"Sonmez","year":"2008","journal-title":"Ophthalmology"},{"key":"bib3","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1001\/archopht.123.7.991","article-title":"The International Classification of Retinopathy of Prematurity revisited","volume":"123","author":"International Committee for the Classification of Retinopathy of P","year":"2005","journal-title":"Arch Ophthalmol"},{"key":"bib4","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S1091-8531(97)90008-2","article-title":"Histopathology and vascular endothelial growth factor in untreated and diode laser-treated retinopathy of prematurity","volume":"1","author":"Young","year":"1997","journal-title":"J AAPOS"},{"key":"bib5","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1001\/archopht.121.12.1684","article-title":"Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial","volume":"121","author":"Early Treatment For Retinopathy Of Prematurity Cooperative","year":"2003","journal-title":"Arch Ophthalmol"},{"key":"bib6","doi-asserted-by":"publisher","first-page":"3107","DOI":"10.1167\/iovs.08-1780","article-title":"Neutralizing VEGF decreases tortuosity and alters endothelial cell division orientation in arterioles and veins in a rat model of ROP: relevance to plus disease","volume":"49","author":"Hartnett","year":"2008","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"bib7","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity","volume":"364","author":"Mintz-Hittner","year":"2011","journal-title":"N Engl J Med"},{"key":"bib8","author":"Lucentis Summary of Product Characteristics"},{"key":"bib9","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1016\/S0140-6736(19)31344-3","article-title":"Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial","volume":"394","author":"Stahl","year":"2019","journal-title":"Lancet"},{"key":"bib10","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1073\/pnas.1010299108","article-title":"Vascular-mesenchymal cross-talk through Vegf and Pdgf drives organ patterning","volume":"108","author":"Cool","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"bib11","doi-asserted-by":"publisher","first-page":"e20153218","DOI":"10.1542\/peds.2015-3218","article-title":"Neurodevelopmental outcomes following bevacizumab injections for retinopathy of prematurity","volume":"137","author":"Morin","year":"2016","journal-title":"Pediatrics"},{"key":"bib12","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.expneurol.2004.01.022","article-title":"New roles for VEGF in nervous tissue\u2013beyond blood vessels","volume":"187","author":"Rosenstein","year":"2004","journal-title":"Exp Neurol"},{"key":"bib13","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1164\/rccm.200611-1660PP","article-title":"Bronchopulmonary dysplasia: where have all the vessels gone? Roles of angiogenic growth factors in chronic lung disease","volume":"175","author":"Thebaud","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"bib14","doi-asserted-by":"publisher","first-page":"F586","DOI":"10.1152\/ajprenal.00221.2016","article-title":"Vascular endothelial growth factor signaling is necessary for expansion of medullary microvessels during postnatal kidney development","volume":"311","author":"Tinning","year":"2016","journal-title":"Am J Physiol Renal Physiol"},{"key":"bib15","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1007\/s00018-015-1907-1","article-title":"Regulation of lung development and regeneration by the vascular system","volume":"72","author":"Woik","year":"2015","journal-title":"Cell Mol Life Sci"},{"key":"bib16","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1167\/iovs.12-10260","article-title":"Pharmacokinetics of ranibizumab in patients with neovascular age-related macular degeneration: a population approach","volume":"54","author":"Xu","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"bib17","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1097\/IAE.0000000000001493","article-title":"Systemic Pharmacokinetics and Pharmacodynamics of Intravitreal Aflibercept, Bevacizumab, and Ranibizumab","volume":"37","author":"Avery","year":"2017","journal-title":"Retina"},{"key":"bib18","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1167\/iovs.14-15842","article-title":"Pharmacokinetics of bevacizumab and its effects on serum VEGF and IGF-1 in infants with retinopathy of prematurity","volume":"56","author":"Kong","year":"2015","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"bib19","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1001\/jamapediatrics.2017.4838","article-title":"Comparing alternative ranibizumab dosages for safety and efficacy in retinopathy of prematurity: a randomized clinical trial","volume":"172","author":"Stahl","year":"2018","journal-title":"JAMA Pediatr"},{"key":"bib20","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1002\/pd.v29:8","article-title":"Fetal eyeball volume: relationship to gestational age and biparietal diameter","volume":"29","author":"Odeh","year":"2009","journal-title":"Prenat Diagn"},{"key":"bib21","doi-asserted-by":"publisher","first-page":"e793","DOI":"10.1097\/SCS.0000000000003133","article-title":"Evaluation of eyeball and orbit in relation to gender and age","volume":"27","author":"Ozer","year":"2016","journal-title":"J Craniofac Surg"},{"key":"bib22","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1167\/iovs.04-0601","article-title":"Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration","volume":"46","author":"Gaudreault","year":"2005","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"bib23","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.ajo.2012.03.047","article-title":"Intraocular pharmacokinetics of ranibizumab following a single intravitreal injection in humans","volume":"154","author":"Krohne","year":"2012","journal-title":"Am J Ophthalmol"},{"key":"bib24","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/j.ophtha.2014.05.015","article-title":"Intravitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity: report on fluorescein angiographic findings","volume":"121","author":"Lepore","year":"2014","journal-title":"Ophthalmology"},{"key":"bib25","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.exer.2007.05.008","article-title":"Ranibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivo","volume":"85","author":"Lowe","year":"2007","journal-title":"Exp Eye Res"},{"key":"bib27","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s00417-017-3878-4","article-title":"Changes in systemic vascular endothelial growth factor levels after intravitreal injection of aflibercept in infants with retinopathy of prematurity","volume":"256","author":"Huang","year":"2018","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"bib28","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/j.ophtha.2016.04.028","article-title":"Clinical Management of Recurrent Retinopathy of Prematurity after Intravitreal Bevacizumab Monotherapy","volume":"123","author":"Mintz-Hittner","year":"2016","journal-title":"Ophthalmology"},{"key":"bib29","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.ajo.2008.05.036","article-title":"Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans","volume":"146","author":"Krohne","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"bib30","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1097\/01.iae.0000242842.14624.e7","article-title":"Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration","volume":"26","author":"Ferrara","year":"2006","journal-title":"Retina"},{"key":"bib31","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s10456-011-9249-6","article-title":"Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab","volume":"15","author":"Papadopoulos","year":"2012","journal-title":"Angiogenesis"},{"key":"bib32","doi-asserted-by":"publisher","first-page":"5512","DOI":"10.1073\/pnas.93.11.5512","article-title":"The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor","volume":"93","author":"Junghans","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"bib33","doi-asserted-by":"publisher","first-page":"e0145375","DOI":"10.1371\/journal.pone.0145375","article-title":"Pre-analytical parameters affecting vascular endothelial growth factor measurement in plasma: identifying confounders","volume":"11","author":"Walz","year":"2016","journal-title":"PLoS One"},{"key":"bib34","doi-asserted-by":"crossref","first-page":"738\u2013744 e731","DOI":"10.1016\/j.ajo.2014.06.009","article-title":"Serum and plasma vascular endothelial growth factor concentrations before and after intravitreal injection of aflibercept or ranibizumab for age-related macular degeneration","volume":"158","author":"Wang","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"bib35","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1097\/IAE.0000000000001209","article-title":"Serum vascular endothelial growth factor after bevacizumab or ranibizumab treatment for retinopathy of prematurity","volume":"37","author":"Wu","year":"2017","journal-title":"Retina"},{"key":"bib36","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.ajo.2011.07.005","article-title":"Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity","volume":"153","author":"Sato","year":"2012","journal-title":"Am J Ophthalmol"},{"key":"bib37","doi-asserted-by":"publisher","first-page":"e154","DOI":"10.1111\/aos.2015.93.issue-2","article-title":"Systemic levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept or ranibizumab in patients with age-related macular degeneration: a randomised, prospective trial","volume":"93","author":"Zehetner","year":"2015","journal-title":"Acta Ophthalmol"},{"key":"bib26","year":"2007"}],"container-title":["Translational Vision Science & Technology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/tvst.arvojournals.org\/article.aspx?articleid=2770537","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,29]],"date-time":"2020-07-29T15:31:30Z","timestamp":1596036690000},"score":1,"resource":{"primary":{"URL":"https:\/\/tvst.arvojournals.org\/article.aspx?articleid=2770537"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,29]]},"references-count":37,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,7,1]]}},"URL":"https:\/\/doi.org\/10.1167\/tvst.9.8.43","relation":{},"ISSN":["2164-2591"],"issn-type":[{"value":"2164-2591","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7,29]]}}}